Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05774951

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Sponsor: AstraZeneca

Conditions Breast Cancer, Early Breast Cancer

Interventions Anastrozole Camizestrant Exemestane Letrozole Tamoxifen

Updated 25 times since 2023 Last updated: Feb 24, 2026 Started: Mar 31, 2023 Primary completion: Apr 20, 2027 Completion: May 29, 2036

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05774951, this PHASE3 trial focuses on Breast Cancer, Early Breast Cancer and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 25 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

25 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3

▶ Show 20 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Aug 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Mar 2025 [monthly]

Recruiting PHASE3
Oct 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3
May 2023 — Jul 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Apr 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aachen, Germany , Aberdeen, United States , Afula, Israel , Aguascalientes, Mexico , Albacete, Spain , Alc. Cuauhtémoc, Mexico , Alcoy, Spain , Alfenas, Brazil , Alicante, Spain and 545 more locations